

AMENDMENTS TO THE CLAIMS

1-102. (Canceled).

103. (Currently amended) A compound selected from the group consisting of hydroxyacetyl-Asn-Tyr-NH₂, hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Gly-Tyr-NH₂, and hydroxyacetyl-Gly-Tyr-OH, ~~acetyl-Asn-Tyr-NH₂, acetyl-Asn-Tyr-OH, acetyl-Gly-Tyr-NH₂, and acetyl-Gly-Tyr-OH;~~ or a pharmaceutically acceptable salt thereof.

104. (Canceled)

105. (Previously presented) A pharmaceutical composition comprising:

- (a) a compound of claim 103 or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

106-107. (Canceled)

108. (Previously presented) The pharmaceutical composition of claim 105, wherein said composition is in a form suitable for oral or parenteral administration.

109. (Previously presented) The pharmaceutical composition of claim 108, wherein said form suitable for oral administration is an enteric tablet.

110. (Previously presented) Hydroxyacetyl-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

111. (Previously presented) A pharmaceutical composition comprising:

- (a) the compound of claim 110, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

112. (Previously presented) The pharmaceutical composition of claim 111, wherein said composition is in a form suitable for oral or parenteral administration.

113. (Previously presented) The pharmaceutical composition of claim 112, wherein said form suitable for oral administration is an enteric tablet.

114. (Previously presented) Hydroxyacetyl-Asn-Tyr-OH, or a pharmaceutically acceptable salt thereof.

115. (Previously presented) A pharmaceutical composition comprising:

- (a) the compound of claim 114, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

116. (Previously presented) The pharmaceutical composition of claim 115, wherein said composition is in a form suitable for oral or parenteral administration.

117. (Previously presented) The pharmaceutical composition of claim 116, wherein said form suitable for oral administration is an enteric tablet.

118. (Previously presented) Hydroxyacetyl-Gly-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

119. (Previously presented) A pharmaceutical composition comprising:

- (a) the compound of claim 118, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

120. (Previously presented) The pharmaceutical composition of claim 119, wherein said composition is in a form suitable for oral or parenteral administration.

121. (Previously presented) The pharmaceutical composition of claim 120, wherein said form suitable for oral administration is an enteric tablet.

122. (Previously presented) Hydroxyacetyl-Gly-Tyr-OH, or a pharmaceutically acceptable salt thereof.

123. (Previously presented) A pharmaceutical composition comprising:

- (a) the compound of claim 122, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

124. (Previously presented) The pharmaceutical composition of claim 123, wherein said composition is in a form suitable for oral or parenteral administration.

125. (Previously presented) The pharmaceutical composition of claim 124, wherein said form suitable for oral administration is an enteric tablet.

126-141. (Cancelled)